Maravai LifeSciences' TriLink BioTechnologies Obtains New Patent From The China National Intellectual Property Administration, Patent Number ZL 2025 1 1246578.X

Maravai Lifesciences Holdings, Inc. Class A

Maravai Lifesciences Holdings, Inc. Class A

MRVI

0.00

TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules. The new patent covers TriLink's full suite of CleanCap® capping analogs, including its latest M6 analog. CleanCap technology is a critical component of the production of synthetic mRNA as drug developers and researchers strive to maximize the impact of mRNA-based therapeutics and vaccines.


 

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.